ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

AN ASSESSMENT OF THE EFFECTIVENESS OF THREE MONTHS MANAGEMENT OF IDIOPATHIC PARKINSON’S DISEASE (I-PD) WITH LEVODOPA (L-DOPA) TO TREAT FATIGUE SEVERITY, HRQOL AND CORTICAL DYSFUNCTIONS

Dr Hasnain Ali, Dr. Wasif Ali, Hamza Bin Zahid

Objectives: The objective of this particular research was to determine the response of levodopa (L-Dopa) against cortical functions, fatigue severity and health-related quality of life; moreover, we also aimed to determine the association between fatigue severity, cortical functions, health-related quality in the post L-Dopa management with I-PD (Idiopathic Parkinson’s Disease). Methods: We conducted this research on a total of fifty patients at DHQ Teaching Hospital Gujranwala from September 2017 to November 2018. These patients were diagnosed with I-PD. Moreover, fifty healthy controls were also part of this particular research. Every participant went through Fatigue Severity Scale, Parkinson’s Disease Questionnaire and Cortical Function Assessment. We tested every patient for these tests before and after the treatment of L-Dopa. Results: I-PD affected patients also had signs of cortical functioning deficits, severe fatigue experiences and deteriorated health-related quality than healthy individuals. The medication of L-Dopa significantly improved the life quality and reduced the fatigue severity in the timeframe of three months. Severe fatigue and deteriorated health also had an association with higher cortical functioning deficits. Cortical functioning also predicted about the fatigue severity and health-related quality. Conclusion: The outcomes clearly conclude that treatment of L-Dopa is very much effective for cortical dysfunctions, severe fatigue and health-related quality of life among the patients of I-PD. Cortical functioning significantly indicates life quality and fatigue factor in the patients of I-PD. Keywords: Health-Related Quality of Life (HRQoL), Idiopathic Parkinson’s Disease (I-PD), Parkinson’s Disease (PD), Cognition, Cortical, Levodopa (L-Dopa) and Chronic Fatigue.

FULL TEXT